Semaglutide
Also known as: Ozempic, Wegovy, Rybelsus
5 notable studies · 6 references
TLDR
Semaglutide is a long-acting GLP-1 receptor agonist with extensive human evidence and FDA-approved uses spanning type 2 diabetes and chronic weight management, with randomized outcome trials additionally demonstrating cardiovascular risk reduction in certain adults with established cardiovascular disease and kidney protection in adults with type 2 diabetes and chronic kidney disease.
Research Supports
- Studied for glycemic control and weight reduction through GLP-1 receptor activation
- Investigated for cardiovascular event reduction in adults with established cardiovascular disease
- Examined for kidney-outcome benefits in type 2 diabetes with chronic kidney disease
- Studied in obesity-related heart failure with preserved ejection fraction (HFpEF)
- Investigated for weight regain and metabolic changes after treatment withdrawal
Observations Reported in Research
- STEP 1: average weight change of -14.9% at 68 weeks vs -2.4% with placebo (2021)
- Reduced major cardiovascular events by 20% relative risk, hazard ratio 0.80 (SELECT, 2023)
- Lowered risk of a composite kidney outcome by 24% in type 2 diabetes with CKD (FLOW, 2024)
- KCCQ clinical summary score improved 16.6 vs 8.7 points at 52 weeks in obesity-related HFpEF (2023)
- Participants regained about two-thirds of lost weight one year after stopping treatment (STEP 1 extension, 2022)
These are brief summaries of what the referenced research examined or reported — not conclusions about safety or effectiveness, and not medical advice. See Notable Studies and Sources & References below for the full context and citations.
At a Glance
Classification: Long-acting glucagon-like peptide-1 receptor (GLP-1R) agonist; acylated GLP-1 analogue
Semaglutide is a long-acting analogue of the endogenous incretin hormone GLP-1. Unlike tirzepatide, retatrutide, mazdutide, and survodutide, semaglutide targets essentially one primary incretin receptor: GLP-1R. That makes it the foundational comparison: Semaglutide → GLP-1 Tirzepatide → GLP-1 + GIP Mazdutide / Survodutide → GLP-1 + glucagon Retatrutide → GLP-1 + GIP + glucagon In STEP 1, once-weekly semaglutide 2.4 mg produced an average 14.9% body-weight reduction at 68 weeks, versus 2.4% with placebo. But semaglutide's evidence now extends well beyond body weight. SELECT demonstrated a 20% relative reduction in major cardiovascular events among adults with established cardiovascular disease and overweight or obesity but without diabetes. FLOW subsequently demonstrated a 24% lower risk of its primary kidney-disease composite outcome in people with type 2 diabetes and chronic kidney disease. Those results have translated into expanded FDA indications rather than remaining merely experimental findings.
What Is Semaglutide?
Semaglutide is an engineered GLP-1 analogue designed to reproduce GLP-1 receptor signaling while remaining active far longer than native GLP-1. Native GLP-1 is rapidly degraded and therefore has a very short biological half-life. Semaglutide incorporates molecular modifications that: • increase resistance to enzymatic degradation, • promote albumin binding, • and greatly prolong systemic exposure. Its half-life is approximately one week, allowing once-weekly subcutaneous administration. An oral formulation is also possible through specialized absorption technology, which is marketed as Rybelsus. Semaglutide activates the GLP-1 receptor, a receptor involved in pancreatic, gastrointestinal, central nervous system, and other physiological processes.
What Are Researchers Studying?
Type 2 diabetes
Semaglutide was initially developed primarily as a treatment for type 2 diabetes. GLP-1 receptor activation increases glucose-dependent insulin secretion and suppresses inappropriate glucagon secretion when glucose is elevated. Large clinical-development programs subsequently demonstrated reductions in HbA1c and body weight across a wide range of adults with type 2 diabetes. Semaglutide is now an established treatment rather than an experimental diabetes compound.
Obesity and body-weight regulation
The STEP clinical program established semaglutide 2.4 mg as an obesity treatment. STEP 1 randomized 1,961 adults with overweight or obesity without diabetes. At 68 weeks: Semaglutide: −14.9% Placebo: −2.4% At least 15% weight reduction was achieved by 50.5% of semaglutide participants versus 4.9% receiving placebo. This provided some of the pivotal evidence supporting semaglutide's modern role in obesity medicine.
Appetite and energy intake
Semaglutide's weight effects are driven substantially through the central regulation of appetite and food intake. GLP-1 receptors participate in neural networks involved in: • satiation • satiety • food reward • hunger • meal size • energy intake This distinction is important. Semaglutide should not simply be described as a drug that “slows the stomach.” Gastric physiology is part of GLP-1 biology, but sustained weight reduction cannot be reduced to delayed gastric emptying alone.
Cardiovascular disease
SELECT changed the semaglutide evidence base substantially. Researchers randomized 17,604 adults aged 45 or older who had established cardiovascular disease and overweight or obesity without diabetes. Major cardiovascular events occurred in: Semaglutide: 6.5% Placebo: 8.0% corresponding to a hazard ratio of 0.80. This provided randomized evidence that semaglutide can reduce cardiovascular events in a defined population rather than merely improving cardiovascular risk factors. The FDA subsequently approved Wegovy to reduce the risk of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke in adults with established cardiovascular disease and overweight or obesity.
Chronic kidney disease
FLOW studied semaglutide specifically in adults with type 2 diabetes and chronic kidney disease. The trial randomized 3,533 participants and followed them for a median 3.4 years. Semaglutide reduced the risk of the primary composite outcome—which included kidney failure, ≥50% sustained loss of kidney function, and kidney- or cardiovascular-related death—by 24% relative to placebo. It also slowed eGFR decline and reduced major cardiovascular events and all-cause mortality in the trial. In January 2025, the FDA expanded Ozempic's indication to include reducing the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes and CKD.
Obesity-related heart failure with preserved ejection fraction
Semaglutide has also been studied in the obesity phenotype of heart failure with preserved ejection fraction (HFpEF). STEP-HFpEF randomized 529 adults with HFpEF and obesity. At 52 weeks, the Kansas City Cardiomyopathy Questionnaire clinical summary score improved by 16.6 points with semaglutide versus 8.7 with placebo. Average body-weight change was: Semaglutide: −13.3% Placebo: −2.6% Six-minute walking distance also improved more with semaglutide. The broader STEP-HFpEF program eventually included 1,145 participants with and without type 2 diabetes and consistently showed improvements in symptoms, physical limitations, exercise function, and body weight. These findings are stronger than simply saying semaglutide improves cardiovascular risk factors, but they should not be generalized to every form of heart failure.
Weight maintenance and treatment withdrawal
Semaglutide has also generated unusually useful evidence about what happens after treatment stops. In the STEP 1 extension, participants who had received semaglutide lost an average 17.3% during treatment in the analyzed extension cohort. One year after treatment withdrawal, they had regained 11.6 percentage points—approximately two-thirds of their prior weight loss. Many cardiometabolic improvements also moved back toward baseline. This supports viewing obesity as a chronic biological disease requiring long-term management rather than assuming a finite medication course permanently resets body weight.
How Does It Work?
Semaglutide binds and activates the GLP-1 receptor. Pancreas When glucose is elevated, GLP-1R activation enhances insulin secretion. It also reduces inappropriate glucagon secretion. Because these actions are glucose-dependent, the biology differs from agents that stimulate insulin secretion irrespective of glucose concentration. Brain GLP-1 receptor signaling influences neural circuits involved in appetite, satiation, reward, and food intake. This is a major contributor to semaglutide-associated weight reduction. Gastrointestinal system GLP-1 signaling affects gastrointestinal physiology, including gastric emptying. The magnitude and persistence of this effect can change during chronic treatment, so “semaglutide works by paralyzing the stomach” is not an accurate description of its mechanism. Cardiovascular and kidney effects Semaglutide improves several factors associated with cardiovascular and kidney disease, including body weight, glycemia, blood pressure, inflammation, and other metabolic variables. However, SELECT and FLOW are important precisely because they evaluated actual clinical outcomes, rather than assuming improvements in biomarkers necessarily translate into fewer events.
What Does the Research Show?
Human research
Human evidence for semaglutide is extensive. It now includes randomized trials involving: • Type 2 diabetes • Obesity • Cardiovascular disease • Chronic kidney disease • HFpEF associated with obesity • Weight-maintenance strategies • Treatment withdrawal • Oral and injectable formulations This means Aminodex should treat semaglutide differently from experimental compounds such as BPC-157 or MOTS-c. For semaglutide, the central uncertainty isn't whether it has meaningful human biological activity. For several indications, clinical efficacy and outcome benefits are already established. The interesting research frontier is now determining how broad those benefits are, how durable they remain, which are independent of weight loss, and which populations benefit most.
Animal research
Animal studies contributed heavily to the development and mechanistic understanding of semaglutide and the broader GLP-1 drug class. Research has examined: • Appetite pathways • Food preference • Energy intake • Glucose regulation • Pancreatic signaling • Cardiovascular physiology • Kidney physiology • Inflammation • Neural GLP-1 pathways For an Aminodex page, however, animal evidence should not dominate. Semaglutide now has direct randomized human evidence for major clinical outcomes, making human trials the appropriate evidentiary center of the profile.
In-vitro research
Cellular research has characterized: • GLP-1 receptor binding • cAMP signaling • receptor internalization • beta-cell responses • peptide stability • albumin binding • receptor trafficking These experiments help explain how semaglutide differs pharmacologically from native GLP-1 and from other GLP-1 receptor agonists. Again, these studies are primarily mechanistic because extensive human evidence is available.
Notable Studies
Once-Weekly Semaglutide in Adults with Overweight or Obesity
humanResearchers randomized 1,961 adults with obesity or overweight plus a weight-related condition, without diabetes, to semaglutide 2.4 mg or placebo alongside lifestyle intervention. At 68 weeks, average body-weight change was −14.9% with semaglutide versus −2.4% with placebo. At least 5%, 10%, and 15% weight reductions occurred substantially more frequently with semaglutide. Nausea and diarrhea were the most common adverse events and were generally transient and mild-to-moderate.
Limitations: The original treatment period lasted 68 weeks. Participants with diabetes were excluded, and the trial did not itself establish cardiovascular-event reduction.
View publication →Weight Regain and Cardiometabolic Effects After Withdrawal of Semaglutide: The STEP 1 Trial Extension
humanResearchers followed 327 participants after semaglutide and lifestyle intervention were discontinued. Participants previously receiving semaglutide had lost an average 17.3% during treatment. One year after withdrawal, they had regained 11.6 percentage points, corresponding to roughly two-thirds of the previous loss. Many cardiometabolic measurements also moved toward their pretreatment values.
Limitations: This was an exploratory extension involving only a subset of the original STEP 1 population. It does not establish that every individual will regain the same proportion of weight or that no alternative maintenance strategy can reduce regain.
View publication →Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
humanSELECT randomized 17,604 adults with established cardiovascular disease and overweight or obesity but without diabetes. Major cardiovascular events occurred in 6.5% receiving semaglutide and 8.0% receiving placebo. The hazard ratio was 0.80, corresponding to a 20% relative reduction in the primary cardiovascular endpoint.
Limitations: Participants already had established cardiovascular disease. The results should not automatically be generalized to people with obesity who do not have established cardiovascular disease.
View publication →Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity
humanResearchers randomized 529 adults with symptomatic HFpEF and obesity. At 52 weeks, semaglutide produced greater improvement in heart-failure-related symptoms and physical limitations, greater weight reduction, and greater improvement in six-minute walking distance than placebo. Average weight change was −13.3% versus −2.6%, while KCCQ-CSS improved by 16.6 versus 8.7 points.
Limitations: The study focused on obesity-related HFpEF and should not be generalized to heart failure with reduced ejection fraction or to every heart-failure phenotype. The trial was primarily designed around symptoms, function, and related endpoints rather than mortality.
View publication →Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes
humanFLOW randomized 3,533 adults with type 2 diabetes and chronic kidney disease to semaglutide 1.0 mg or placebo. Median follow-up was 3.4 years. The risk of the primary composite kidney outcome was 24% lower with semaglutide. Semaglutide also slowed annual eGFR decline, reduced major cardiovascular events by 18%, and reduced all-cause mortality by 20% within the trial.
Limitations: The population specifically had type 2 diabetes and CKD. These results should not automatically be interpreted as equivalent kidney-outcome evidence for people with CKD who do not have diabetes.
View publication →What We Still Don't Know
Despite having one of the strongest evidence bases in this entire Aminodex library, meaningful questions remain: • Effects of decades-long treatment • Optimal duration of obesity treatment • Best strategies for maintaining weight after discontinuation • Whether gradual withdrawal materially changes weight recurrence • How much cardiovascular benefit is mediated by weight loss versus other mechanisms • How much kidney protection is mediated by glycemic, hemodynamic, weight, inflammatory, or direct renal pathways • Long-term body-composition changes, including preservation of lean mass • Which individuals are unusually strong or weak responders • Long-term comparative outcomes versus tirzepatide • Comparative cardiovascular outcomes versus newer multi-receptor agonists • Whether newer combinations can substantially improve efficacy without sacrificing tolerability • Effects in additional liver, neurologic, addiction, inflammatory, and other conditions currently being investigated Notably, a randomized study specifically testing gradual tapering versus abrupt semaglutide withdrawal is now underway, illustrating that even something as seemingly basic as how best to stop treatment remains an open research question.
Related Compounds
Recent publications
Latest titles from PubMed, not reviewed by Aminodex. Not an endorsement. See all on PubMed ↗
Take the Semaglutide research with you.
Get the Aminodex Semaglutide Brief—a concise summary of the research, notable studies, evidence types, limitations, and references.
One-time email. We do not add you to any mailing list.
Sources & References
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021;384:989–1002. doi:10.1056/NEJMoa2032183.
- Wilding JPH, Batterham RL, Davies M, et al. Weight Regain and Cardiometabolic Effects After Withdrawal of Semaglutide: The STEP 1 Trial Extension. Diabetes, Obesity and Metabolism. 2022;24:1553–1564. doi:10.1111/dom.14725.
- Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. New England Journal of Medicine. 2023.
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine. 2023;389:2221–2232. doi:10.1056/NEJMoa2307563.
- Perkovic V, Tuttle KR, Rossing P, et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. New England Journal of Medicine. 2024;391:109–121. doi:10.1056/NEJMoa2403347.
- U.S. Food and Drug Administration. Wegovy supplemental approval for reduction of major adverse cardiovascular events. March 8, 2024.
Supplier Listings
A directory of relevant research suppliers for this compound is not yet available.